Asset
Letermovir
Merck & Company Inc. Common Stock (new)
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $295.0M |
| Q1 2026 | $272.0M |
| Q4 2025 | $276.0M |
| Q3 2025 | $266.0M |
| Q2 2025 | $228.0M |
| Q1 2025 | $208.0M |
| Q4 2024 | $215.0M |
| Q3 2024 | $208.0M |
| Q2 2024 | $188.0M |
| Q1 2024 | $174.0M |
| Q4 2023 | $175.0M |
| Q3 2023 | $157.0M |
| Q2 2023 | $143.0M |
| Q1 2023 | $129.0M |
| Q4 2022 | $118.0M |
| Q3 2022 | $114.0M |
| Q2 2022 | $103.0M |
| Q1 2022 | $94.0M |
| Q4 2021 | $100.0M |
| Q3 2021 | $96.0M |
| Q2 2021 | $93.0M |
| Q1 2021 | $82.0M |
| Q4 2020 | $81.0M |
| Q3 2020 | $77.0M |
| Q2 2020 | $63.0M |
| Q1 2020 | $60.0M |
| Q4 2019 | $50.0M |
| Q3 2019 | $45.0M |
| Q2 2019 | $38.0M |
| Q1 2019 | $32.0M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07199465 | phase1 | recruiting | 2026-03-30 | 2028-04-14 | Merck Sharp & Dohme LLC | A Clinical Study of Letermovir (MK-8228) in Children and Adolescents Who Receive a Kidney Transplant (KT) (MK-8228-077) |
| NCT05763823 | phase3 | completed | 2023-03-24 | 2024-04-18 | Merck Sharp & Dohme LLC | A Study of Letermovir (MK-8228) to Evaluate Efficacy and Safety for Prevention of Cytomegalovirus Infection in Chinese Hematopoietic Stem Cell Transplant Recipients (MK-8228-045) |
| NCT03930615 | phase3 | completed | 2019-06-21 | 2021-10-27 | Merck Sharp & Dohme LLC | Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) |
| NCT02137772 | phase3 | completed | 2014-06-06 | 2016-08-08 | Merck Sharp & Dohme LLC | Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) |
| NCT03940586 | phase2 | completed | 2019-08-08 | 2023-01-04 | Merck Sharp & Dohme LLC | Letermovir Treatment in Pediatric Participants Following Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) (MK-8228-030) |
FDA applications (3)
| Application | Type | Applicant |
|---|---|---|
| NDA 209939 | NDA | MERCK SHARP AND DOHME CORP |
| NDA 209940 | NDA | MERCK SHARP AND DOHME CORP |
| NDA 219104 | NDA | MERCK SHARP AND DOHME LLC |
Marketed products (6)
- PREVYMIS
- PREVYMIS
- PREVYMIS
- PREVYMIS
- PREVYMIS
- PREVYMIS